FDA Hears Fight Over Who Can Give Psychedelic Therapy

The hearing FDA scheduled two months ago finally happened on September 14, and it surfaced exactly the fight its own notice had tried to fence off. FDA is not seeking comment on whether any psychedelic drug works — that question sits with pending applications. What it wanted input on was the infrastructure around a future approval: training, safety, access, and data. On access, it got a pointed answer: a single line in July's clinical trial guidance, requiring an on-call physician to reach a patient within 15 minutes of a non-physician-led dosing session, could keep the therapy out of exactly the rural and underserved areas that most need it, clinic operators told the panel.

The question the July notice deferred

When FDA announced this hearing on 14 July — the same day it finalized its clinical trial guidance for psychedelic drugs — it drew careful boundaries around what it would discuss. Not the safety or effectiveness of any pending application. Not scheduling under the Controlled Substances Act. Not legalization. What was in bounds: what the therapeutic use of these drugs should look like once one is approved, across four areas — provider training and credentialing, patient safety, access, and data standardization. September 14 is where the agency found out what the field actually thinks.

The 15-minute rule becomes the hearing's center of gravity

Much of the current wave of psychedelic drug development has moved away from the unsupervised, take-home model used in state programs in Oregon and Colorado, toward supervised, in-clinic dosing sessions with a monitor present throughout. FDA's July guidance builds a physician-availability backstop into that model: if the person directly monitoring a session is not a physician, a physician must be able to reach the patient within 15 minutes. According to testimony summarized by Fierce Healthcare, Jon Dalton of the Nevada Coalition for Psychedelic Medicines argued that requirement, however reasonable it looks in a well-staffed academic medical center, could be effectively unmeetable for a qualified clinic in a rural county — excluding exactly the underserved patients that expanded access is supposed to reach.

That tension is precisely what the July notice's "access" topic asked about: evidence needs for reimbursement, provider–payer coordination, and implementation practicalities like staffing, scheduling, and telehealth screening. Per BioSpace's coverage of the hearing, most testimony on this point came from education and credentialing organizations serving would-be psychedelic providers, who pushed FDA to widen the workforce eligible to run and monitor sessions rather than loosen the safety backstop itself — training more people to meet the 15-minute standard, rather than relaxing it.

A dissent from the room's broad support

Public comment ahead of the hearing leaned favorable, drawing support from patients, physicians, interventional psychiatry centers, and, per BioSpace's reporting, HHS, the White House, and the Department of Veterans Affairs. The hearing's most-quoted dissent came from Kevin Sabet, head of the Foundation for Drug Policy Solutions and a former White House adviser on drug control policy, who told the panel that psychedelics "should earn approval the way any other class of drug does — through science and trials, not politics or podcasters." It is a direct challenge to the administration's own framing of the push, which traces to Executive Order 14401, "Accelerating Medical Treatments for Serious Mental Illness," issued 18 April 2026.

CDER's new director puts his name on the framework

The hearing landed days after Michael Davis was confirmed as CDER's permanent director — part of the same personnel action, alongside a new CBER director and the agency's first Deputy Commissioner for Technology and AI, that Regulatory News covered on September 12. On 10 September, days ahead of the hearing, Davis co-authored a New England Journal of Medicine commentary, "Psychedelic Therapies in the United States — Balancing State and Federal Oversight," with Teresa Buracchio, director of CDER's Office of Neuroscience, and Tiffany Farchione and Bernard Fischer, who lead that office's Division of Psychiatry. Davis previously served as chief medical officer at Usona Institute, a psilocybin-research nonprofit whose programs have themselves received FDA national priority vouchers — a background that puts the new director's personal expertise squarely behind the policy he is now shaping.

“Psychedelics should earn approval the way any other class of drug does — through science and trials, not politics or podcasters.” Kevin Sabet, Ph.D., Foundation for Drug Policy Solutions, at FDA's September 14 hearing

What comes next

The hearing was transcribed, and FDA will post that transcript to Docket FDA-2026-N-7542, where written comments remain open until 5 October 2026 — the deadline the July notice set, and one FDA said it would weigh "equally with oral presentations." Nothing said on 14 September binds the agency to any particular label condition; the four topic areas exist to inform whatever post-approval framework eventually accompanies a first psychedelic-drug approval, which the industry press covering the hearing described as increasingly likely, if not yet dated. Sponsors building REMS-like monitoring and credentialing plans now have a public record of exactly which provisions clinics consider workable — and which one, so far, draws the most pushback.

Frequently asked questions

What happened at FDA's September 14 hearing?

FDA held the part 15 public hearing it announced in July, at its White Oak campus (Building 31, Room 1503) and online, taking testimony from more than 30 commenters on provider training and credentialing, patient safety, access, and data collection for the future therapeutic use of psychedelic drugs in supervised settings.

What was the main point of disagreement?

Access. FDA's July clinical trial guidance requires an on-call physician to be able to reach a patient within 15 minutes when a non-physician monitors a dosing session. Workforce and clinic groups, including the Nevada Coalition for Psychedelic Medicines, testified that requirement could exclude qualified clinics in rural or remote areas.

Did anyone testify against moving quickly?

Yes. Kevin Sabet of the Foundation for Drug Policy Solutions, a former White House drug policy adviser, argued psychedelics should earn approval "through science and trials, not politics or podcasters" — a dissent from the broadly favorable tenor of most testimony.

How does this connect to FDA's own leadership?

Days after being confirmed as CDER's permanent director, Michael Davis co-authored a New England Journal of Medicine commentary with three other CDER officials laying out the agency's psychedelic-drug framework ahead of the hearing. Davis previously served as chief medical officer at Usona Institute, a psilocybin-research nonprofit.